BioAtla (BCAB) Competitors $0.83 +0.03 (+3.88%) Closing price 03:58 PM EasternExtended Trading$0.84 +0.01 (+1.20%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCAB vs. ACTU, CCCC, PYXS, CTOR, THTX, ACOG, NVCT, NKTX, MOLN, and GLSIShould you be buying BioAtla stock or one of its competitors? The main competitors of BioAtla include Actuate Therapeutics (ACTU), C4 Therapeutics (CCCC), Pyxis Oncology (PYXS), Citius Oncology (CTOR), Theratechnologies (THTX), Alpha Cognition (ACOG), Nuvectis Pharma (NVCT), Nkarta (NKTX), Molecular Partners (MOLN), and Greenwich LifeSciences (GLSI). These companies are all part of the "pharmaceutical products" industry. BioAtla vs. Its Competitors Actuate Therapeutics C4 Therapeutics Pyxis Oncology Citius Oncology Theratechnologies Alpha Cognition Nuvectis Pharma Nkarta Molecular Partners Greenwich LifeSciences BioAtla (NASDAQ:BCAB) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings. Do insiders and institutionals hold more shares of BCAB or ACTU? 77.2% of BioAtla shares are held by institutional investors. 11.2% of BioAtla shares are held by insiders. Comparatively, 69.3% of Actuate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, BCAB or ACTU? BioAtla has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Actuate Therapeutics has a beta of -0.23, suggesting that its share price is 123% less volatile than the S&P 500. Do analysts prefer BCAB or ACTU? Actuate Therapeutics has a consensus target price of $20.33, suggesting a potential upside of 161.52%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Actuate Therapeutics is more favorable than BioAtla.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75Actuate Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media favor BCAB or ACTU? In the previous week, BioAtla had 1 more articles in the media than Actuate Therapeutics. MarketBeat recorded 2 mentions for BioAtla and 1 mentions for Actuate Therapeutics. BioAtla's average media sentiment score of 0.95 beat Actuate Therapeutics' score of 0.83 indicating that BioAtla is being referred to more favorably in the media. Company Overall Sentiment BioAtla Positive Actuate Therapeutics Positive Which has better valuation and earnings, BCAB or ACTU? Actuate Therapeutics has lower revenue, but higher earnings than BioAtla. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioAtla$11M4.44-$69.78M-$1.10-0.76Actuate TherapeuticsN/AN/A-$27.28MN/AN/A Is BCAB or ACTU more profitable? Actuate Therapeutics' return on equity of 0.00% beat BioAtla's return on equity.Company Net Margins Return on Equity Return on Assets BioAtlaN/A -1,177.18% -137.51% Actuate Therapeutics N/A N/A -281.83% SummaryBioAtla and Actuate Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Get BioAtla News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAB vs. The Competition Export to ExcelMetricBioAtlaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.86M$3.39B$6.04B$10.49BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-0.7622.9085.1927.32Price / Sales4.44269.18516.16194.55Price / CashN/A46.9537.5761.53Price / Book3.3310.5312.426.81Net Income-$69.78M-$52.58M$3.32B$276.59M7 Day Performance-8.92%1.06%0.80%0.15%1 Month Performance19.73%16.05%10.52%8.17%1 Year Performance-57.33%18.41%76.14%35.50% BioAtla Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCABBioAtla0.5961 of 5 stars$0.83+3.9%N/A-60.2%$48.86M$11M-0.7660Analyst ForecastACTUActuate Therapeutics1.9165 of 5 stars$7.02+0.6%$20.33+189.6%+2.0%$162.24MN/A0.0010CCCCC4 Therapeutics3.7672 of 5 stars$2.28+0.4%$8.50+272.8%-65.6%$161.56M$35.58M-1.44150PYXSPyxis Oncology2.0756 of 5 stars$2.47-3.9%$7.75+213.8%+1.3%$159.39M$16.15M-1.5460News CoverageAnalyst UpgradeCTORCitius Oncology3.045 of 5 stars$1.87-1.1%$6.00+220.9%+61.9%$157.84MN/A0.00N/AGap UpTHTXTheratechnologiesN/A$3.42+0.9%N/A+174.3%$157.21M$84.38M-17.99140High Trading VolumeACOGAlpha Cognition2.9572 of 5 stars$7.40-1.1%$20.00+170.3%N/A$156.35MN/A-4.63N/ANVCTNuvectis Pharma3.2504 of 5 stars$6.05+0.7%$15.33+153.4%-6.5%$152.87MN/A-5.178NKTXNkarta2.3955 of 5 stars$2.15+0.9%$13.60+532.6%-39.3%$151.28MN/A-1.45140High Trading VolumeMOLNMolecular Partners1.4971 of 5 stars$3.72+0.3%$8.00+115.0%-26.7%$149.79M$5.65M-1.79180News CoverageAnalyst ForecastGLSIGreenwich LifeSciences1.2458 of 5 stars$11.28+3.4%$42.00+272.3%-23.7%$148.71MN/A-8.293Analyst Forecast Related Companies and Tools Related Companies ACTU Alternatives CCCC Alternatives PYXS Alternatives CTOR Alternatives THTX Alternatives ACOG Alternatives NVCT Alternatives NKTX Alternatives MOLN Alternatives GLSI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAB) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
